Legend Biotech Corp ADR LEGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LEGN is a good fit for your portfolio.
News
-
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
-
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
-
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
-
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
-
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
-
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
-
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
-
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
Trading Information
- Previous Close Price
- $45.30
- Day Range
- $45.06–46.47
- 52-Week Range
- $44.06–77.32
- Bid/Ask
- $44.20 / $47.52
- Market Cap
- $8.21 Bil
- Volume/Avg
- 963,252 / 979,295
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 27.88
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1,800
- Website
- https://www.legendbiotech.com
Valuation
|
Metric
|
LEGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.86 |
Price/Sales | 27.88 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LEGN
|
|---|---|
Quick Ratio | 6.77 |
Current Ratio | 6.92 |
Interest Coverage | −25.37 |
Quick Ratio
LEGN
Profitability
|
Metric
|
LEGN
|
|---|---|
Return on Assets (Normalized) | −21.92% |
Return on Equity (Normalized) | −34.02% |
Return on Invested Capital (Normalized) | −28.02% |
Return on Assets
LEGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Krfwjljgvy | Fmnf | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Csjwhzl | Cwnkwt | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Flfthknz | Tgwjb | $98.3 Bil | |
MRNA
| Moderna Inc | Wmhrjnt | Ccjq | $42.7 Bil | |
ARGX
| argenx SE ADR | Bnhpwfy | Nvhh | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Xhszgqtk | Hjy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rdjqdyh | Xyystv | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ksnwqnxj | Srxpvhh | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dsnqfdbc | Pcyfhh | $12.7 Bil | |
INCY
| Incyte Corp | Ytmmwrjvf | Bwcqgg | $11.8 Bil |